AU731656B2 - Method of treating heart failure - Google Patents

Method of treating heart failure Download PDF

Info

Publication number
AU731656B2
AU731656B2 AU81740/98A AU8174098A AU731656B2 AU 731656 B2 AU731656 B2 AU 731656B2 AU 81740/98 A AU81740/98 A AU 81740/98A AU 8174098 A AU8174098 A AU 8174098A AU 731656 B2 AU731656 B2 AU 731656B2
Authority
AU
Australia
Prior art keywords
dose
adrenergic receptor
heart failure
metoprolol
positive inotropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU81740/98A
Other languages
English (en)
Other versions
AU8174098A (en
Inventor
Michael R. Bristow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder filed Critical University of Colorado Boulder
Publication of AU8174098A publication Critical patent/AU8174098A/en
Application granted granted Critical
Publication of AU731656B2 publication Critical patent/AU731656B2/en
Assigned to UNIVERSITY TECHNOLOGY CORPORATION reassignment UNIVERSITY TECHNOLOGY CORPORATION Alteration of Name(s) in Register under S187 Assignors: BRISTOW, MICHAEL R.
Assigned to REGENTS OF THE UNIVERSITY OF COLORADO, THE reassignment REGENTS OF THE UNIVERSITY OF COLORADO, THE Alteration of Name(s) in Register under S187 Assignors: UNIVERSITY TECHNOLOGY CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU81740/98A 1997-06-25 1998-06-24 Method of treating heart failure Ceased AU731656B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5067497P 1997-06-25 1997-06-25
US60/050674 1997-06-25
PCT/US1998/013442 WO1998058638A1 (en) 1997-06-25 1998-06-24 Method of treating heart failure

Publications (2)

Publication Number Publication Date
AU8174098A AU8174098A (en) 1999-01-04
AU731656B2 true AU731656B2 (en) 2001-04-05

Family

ID=21966696

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81740/98A Ceased AU731656B2 (en) 1997-06-25 1998-06-24 Method of treating heart failure

Country Status (6)

Country Link
US (1) US5998458A (cg-RX-API-DMAC7.html)
EP (1) EP1017376A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002508766A (cg-RX-API-DMAC7.html)
AU (1) AU731656B2 (cg-RX-API-DMAC7.html)
CA (1) CA2295094A1 (cg-RX-API-DMAC7.html)
WO (1) WO1998058638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
FI20011464A0 (fi) 2001-07-04 2001-07-04 Orion Corp Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
US7020521B1 (en) 2002-11-08 2006-03-28 Pacesetter, Inc. Methods and apparatus for detecting and/or monitoring heart failure
JP2007511487A (ja) 2003-11-17 2007-05-10 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼiv阻害剤の使用
US20060018970A1 (en) * 2003-12-12 2006-01-26 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
JP2007530566A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド (r)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用
EP1737448A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
CN104644627A (zh) 2004-09-14 2015-05-27 科罗拉多大学董事会 基于基因靶向使用布新洛尔的治疗方法
CA2610022A1 (en) 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
WO2007014029A2 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of Colorado, A Body Corporate Yin yang 1 as a treatment for cardiac hypertrophy and heart failure
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
CN110520116A (zh) * 2017-01-03 2019-11-29 卡尔迪奥克斯尔制药公司 供硝酰化合物的给予方法
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
EP4146215A4 (en) * 2020-05-04 2024-05-01 Imbria Pharmaceuticals, Inc. DOSING METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE354851B (cg-RX-API-DMAC7.html) * 1970-02-18 1973-03-26 Haessle Ab
US4405635A (en) * 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals

Also Published As

Publication number Publication date
WO1998058638A1 (en) 1998-12-30
CA2295094A1 (en) 1998-12-30
EP1017376A4 (en) 2002-10-25
EP1017376A1 (en) 2000-07-12
US5998458A (en) 1999-12-07
AU8174098A (en) 1999-01-04
JP2002508766A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
US5998458A (en) Method of treating heart failure
JP2022020624A (ja) 心房拡大又はリモデリングを特徴とする疾患を治療するためのnep阻害剤
Zimmerman et al. Vasopressors and inotropes
US9457017B2 (en) Treatment of heart failure
Chioncel et al. Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
WO2022232650A1 (en) Methods for reducing agt expression
Hoffman Phosphodiesterase inhibitors
TW202313021A (zh) 作為強心劑之六氫吡啶脲衍生物
WO2009066085A1 (en) Treatment of heart failure with normal ejection fraction
Anderson Management of beta-adrenergic blocker poisoning
CA2485600C (en) 5-ht4 receptor antagonists for the treatment of heart failure
Kiriazis et al. Chronic activation of the low affinity site of β1‐adrenoceptors stimulates haemodynamics but exacerbates pressure‐overload cardiac remodelling
Kikura et al. New cardiac drugs
Molina et al. Alcohol does not modulate the augmented acetylcholine-induced vasodilatory response in hemorrhaged rodents
Van Zwieten Renewed interest in centrally acting antihypertensive drugs
EP3124019B1 (en) Substance selected among midodrine, a pharmaceutical salt and the active metabolite thereof, for use in the treatment of obstructive cardiopathy
Levy Support of the perioperative failing heart with preexisting ventricular dysfunction: currently available options
Young et al. Mg2+ efflux from the isolated perfused rabbit heart is mediated by two states of the β1-adrenergic receptor
Lomivorotov et al. Perfusion separation challenge
Keskin et al. Effect of Levosimendan and Milrinone Combination in Chronic Kidney Disease Patients Who Underwent Cardiac Surgery
White et al. Beneficial effects of prolonged low dose dopamine in hospitalized patients with severe refractory heart failure
CN122055157A (zh) 降低左心室肥大患者的心血管事件风险的方法
Fujimoto et al. Hemodynamic Changes Following Landiolol Initiation in Patients With Critical Illness Who Developed Tachycardia During Dobutamine Infusion: A Retrospective Observational Study
EA047888B1 (ru) Применение производных пиперидин мочевины в качестве инотропных агентов
Crudu et al. Renal effects of combination infusion of high dose furosemide and nesiritide in patients with acutely decompensated heart failure

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: UNIVERSITY TECHNOLOGY CORPORATION

Free format text: FORMER OWNER WAS: MICHAEL R. BRISTOW

PC Assignment registered

Owner name: THE REGENTS OF THE UNIVERSITY OF COLORADO

Free format text: FORMER OWNER WAS: UNIVERSITY TECHNOLOGY CORPORATION